Korea Investment CORP Has $13.86 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Korea Investment CORP increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,289 shares of the biotechnology company's stock after acquiring an additional 2,300 shares during the period. Korea Investment CORP owned about 0.09% of United Therapeutics worth $13,863,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wealthfront Advisers LLC raised its stake in shares of United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after acquiring an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. raised its position in United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after purchasing an additional 32,213 shares during the last quarter. Geode Capital Management LLC lifted its holdings in United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock worth $391,459,000 after buying an additional 45,566 shares in the last quarter. FMR LLC boosted its position in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after buying an additional 314,004 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock valued at $210,869,000 after buying an additional 30,931 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on UTHR. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

Insider Buying and Selling

In related news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 72,500 shares of company stock valued at $26,134,500. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $5.04 during midday trading on Thursday, reaching $307.22. 223,988 shares of the stock were exchanged, compared to its average volume of 449,364. United Therapeutics Co. has a 12 month low of $227.75 and a 12 month high of $417.82. The business has a 50-day simple moving average of $336.64 and a two-hundred day simple moving average of $355.09. The company has a market capitalization of $13.80 billion, a price-to-earnings ratio of 13.49, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the company earned $4.36 earnings per share. Equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.